TICKERNOMICS Sign up
Last Update: 2023-10-04 11:35:53
TCR2 THERAPEUTICS INC. ( TCRR ) https://www.tcr2.com
1.48USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
-18.23%
TCRR
SPY
36.71%
-92.67%
TCRR
SPY
70.96%
TCRR
0.00%
SPY
262.36%
TCRR
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
58.05
-46.28
3.91
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.36
0.00
0.57
-207.01
0.00
0.37
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.69
-89.61
-73.96
0.00
Other Earnings and Cash Flow Stats:
TCR2 THERAPEUTICS INC. ( TCRR ) Net Income TTM ($MM) is -131.72
TCR2 THERAPEUTICS INC. ( TCRR ) Operating Income TTM ($MM) is -133.58
TCR2 THERAPEUTICS INC. ( TCRR ) Owners' Earnings Annual ($MM) is 0.00
TCR2 THERAPEUTICS INC. ( TCRR ) Current Price to Owners' Earnings ratio is 0.00
TCR2 THERAPEUTICS INC. ( TCRR ) EBITDA TTM ($MM) is -130.67
TCR2 THERAPEUTICS INC. ( TCRR ) EBITDA Margin is 0.00%
Capital Allocation:
TCR2 THERAPEUTICS INC. ( TCRR ) has paid 0.00 dividends per share and bought back -0.600233 million shares in the past 12 months
TCR2 THERAPEUTICS INC. ( TCRR ) has reduced its debt by 52.251 million USD in the last 12 months
Capital Structure:
TCR2 THERAPEUTICS INC. ( TCRR ) Interest-bearing Debt ($MM) as of last quarter is 5
TCR2 THERAPEUTICS INC. ( TCRR ) Annual Working Capital Investments ($MM) are -5
TCR2 THERAPEUTICS INC. ( TCRR ) Book Value ($MM) as of last quarter is 101
TCR2 THERAPEUTICS INC. ( TCRR ) Debt/Capital as of last quarter is 5%
Other Balance Sheet Stats:
TCR2 THERAPEUTICS INC. ( TCRR ) has 14 million in cash on hand as of last quarter
TCR2 THERAPEUTICS INC. ( TCRR ) has 47 million of liabilities due within 12 months, and long term debt 0 as of last quarter
TCR2 THERAPEUTICS INC. ( TCRR ) has 39 common shares outstanding as of last quarter
TCR2 THERAPEUTICS INC. ( TCRR ) has 205 million USD of preferred stock value
Academic Scores:
TCR2 THERAPEUTICS INC. ( TCRR ) Altman Z-Score is -7.62 as of last quarter
TCR2 THERAPEUTICS INC. ( TCRR ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
TCR2 THERAPEUTICS INC. ( TCRR ) largest shareholder is Long Focus Capital Management, LLC owning 566270 shares at 0.84 ($MM) value
Kevin C Tang(an insider) Bought 50000 shares of TCR2 THERAPEUTICS INC. ( TCRR ) for the amount of $86000.00 on 2023-05-25
1.49% of TCR2 THERAPEUTICS INC. ( TCRR ) is held by insiders, and 54.32% is held by institutions
TCR2 THERAPEUTICS INC. ( TCRR ) went public on 2019-02-14
Other TCR2 THERAPEUTICS INC. ( TCRR ) financial metrics:
FCF:-129.68
Unlevered Free Cash Flow:-150.67
EPS:-4.18
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-159.47
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About TCR2 THERAPEUTICS INC. ( TCRR ) :
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.